nodes	percent_of_prediction	percent_of_DWPC	metapath
Methotrexate—germ cell cancer—malignant glioma	0.709	1	CtDrD
Methotrexate—Partial seizures—Temozolomide—malignant glioma	0.0102	0.0785	CcSEcCtD
Methotrexate—SLC22A8—choroid plexus—malignant glioma	0.00622	0.0935	CbGeAlD
Methotrexate—Lung fibrosis interstitial—Carmustine—malignant glioma	0.00551	0.0425	CcSEcCtD
Methotrexate—Pneumocystis jirovecii pneumonia—Temozolomide—malignant glioma	0.00489	0.0377	CcSEcCtD
Methotrexate—Alveolitis—Temozolomide—malignant glioma	0.00489	0.0377	CcSEcCtD
Methotrexate—Monoplegia—Carmustine—malignant glioma	0.0041	0.0317	CcSEcCtD
Methotrexate—Gastrointestinal toxicity—Carmustine—malignant glioma	0.00387	0.0298	CcSEcCtD
Methotrexate—Lung infection—Temozolomide—malignant glioma	0.00374	0.0288	CcSEcCtD
Methotrexate—Hemiparesis—Temozolomide—malignant glioma	0.00293	0.0226	CcSEcCtD
Methotrexate—Pulmonary toxicity—Carmustine—malignant glioma	0.0028	0.0216	CcSEcCtD
Methotrexate—Infertility—Carmustine—malignant glioma	0.00243	0.0188	CcSEcCtD
Methotrexate—Infertility—Temozolomide—malignant glioma	0.00235	0.0181	CcSEcCtD
Methotrexate—Fibrosis—Carmustine—malignant glioma	0.00222	0.0171	CcSEcCtD
Methotrexate—ABCC11—embryo—malignant glioma	0.002	0.0301	CbGeAlD
Methotrexate—Skin necrosis—Carmustine—malignant glioma	0.00182	0.014	CcSEcCtD
Methotrexate—Paresis—Temozolomide—malignant glioma	0.00168	0.013	CcSEcCtD
Methotrexate—Opportunistic infection—Temozolomide—malignant glioma	0.00152	0.0117	CcSEcCtD
Methotrexate—MTHFR—blood vessel—malignant glioma	0.00147	0.0221	CbGeAlD
Methotrexate—Impaired healing—Carmustine—malignant glioma	0.00147	0.0113	CcSEcCtD
Methotrexate—Pulmonary fibrosis—Carmustine—malignant glioma	0.00144	0.0111	CcSEcCtD
Methotrexate—Pulmonary fibrosis—Temozolomide—malignant glioma	0.00139	0.0108	CcSEcCtD
Methotrexate—Lung infiltration—Carmustine—malignant glioma	0.00135	0.0104	CcSEcCtD
Methotrexate—Interstitial pneumonia—Temozolomide—malignant glioma	0.00127	0.00979	CcSEcCtD
Methotrexate—Azotaemia—Carmustine—malignant glioma	0.00119	0.00919	CcSEcCtD
Methotrexate—ATIC—embryo—malignant glioma	0.00118	0.0178	CbGeAlD
Methotrexate—GGH—telencephalon—malignant glioma	0.00113	0.017	CbGeAlD
Methotrexate—ATIC—brainstem—malignant glioma	0.00108	0.0163	CbGeAlD
Methotrexate—FPGS—retina—malignant glioma	0.00108	0.0162	CbGeAlD
Methotrexate—Skin hyperpigmentation—Carmustine—malignant glioma	0.00107	0.00823	CcSEcCtD
Methotrexate—Febrile neutropenia—Carmustine—malignant glioma	0.00106	0.00814	CcSEcCtD
Methotrexate—ATIC—retina—malignant glioma	0.00104	0.0157	CbGeAlD
Methotrexate—Febrile neutropenia—Temozolomide—malignant glioma	0.00102	0.00787	CcSEcCtD
Methotrexate—Deep vein thrombosis—Temozolomide—malignant glioma	0.00101	0.00778	CcSEcCtD
Methotrexate—Encephalopathy—Carmustine—malignant glioma	0.000989	0.00763	CcSEcCtD
Methotrexate—Aphasia—Carmustine—malignant glioma	0.000979	0.00755	CcSEcCtD
Methotrexate—FOLR1—central nervous system—malignant glioma	0.000966	0.0145	CbGeAlD
Methotrexate—ATIC—telencephalon—malignant glioma	0.00096	0.0144	CbGeAlD
Methotrexate—Embolism—Temozolomide—malignant glioma	0.000956	0.00737	CcSEcCtD
Methotrexate—Cyst—Carmustine—malignant glioma	0.00095	0.00732	CcSEcCtD
Methotrexate—Aphasia—Temozolomide—malignant glioma	0.000946	0.0073	CcSEcCtD
Methotrexate—FOLR1—cerebellum—malignant glioma	0.000944	0.0142	CbGeAlD
Methotrexate—Burning sensation—Carmustine—malignant glioma	0.000914	0.00705	CcSEcCtD
Methotrexate—Interstitial lung disease—Carmustine—malignant glioma	0.000897	0.00692	CcSEcCtD
Methotrexate—GGH—medulla oblongata—malignant glioma	0.000887	0.0133	CbGeAlD
Methotrexate—Interstitial lung disease—Temozolomide—malignant glioma	0.000867	0.00669	CcSEcCtD
Methotrexate—Lung disorder—Temozolomide—malignant glioma	0.000867	0.00669	CcSEcCtD
Methotrexate—Stupor—Carmustine—malignant glioma	0.00085	0.00656	CcSEcCtD
Methotrexate—SLC19A1—central nervous system—malignant glioma	0.000847	0.0127	CbGeAlD
Methotrexate—SLC19A1—cerebellum—malignant glioma	0.000828	0.0124	CbGeAlD
Methotrexate—Hepatotoxicity—Carmustine—malignant glioma	0.000822	0.00634	CcSEcCtD
Methotrexate—Herpes zoster—Temozolomide—malignant glioma	0.000815	0.00628	CcSEcCtD
Methotrexate—GGH—midbrain—malignant glioma	0.000811	0.0122	CbGeAlD
Methotrexate—Necrosis—Carmustine—malignant glioma	0.000809	0.00624	CcSEcCtD
Methotrexate—SLC46A1—spinal cord—malignant glioma	0.000804	0.0121	CbGeAlD
Methotrexate—Abscess—Carmustine—malignant glioma	0.000802	0.00619	CcSEcCtD
Methotrexate—SLCO1C1—telencephalon—malignant glioma	0.000798	0.012	CbGeAlD
Methotrexate—Hepatotoxicity—Temozolomide—malignant glioma	0.000794	0.00613	CcSEcCtD
Methotrexate—DHFR—embryo—malignant glioma	0.000793	0.0119	CbGeAlD
Methotrexate—GGH—spinal cord—malignant glioma	0.000791	0.0119	CbGeAlD
Methotrexate—FPGS—medulla oblongata—malignant glioma	0.00078	0.0117	CbGeAlD
Methotrexate—FOLR1—brain—malignant glioma	0.000767	0.0115	CbGeAlD
Methotrexate—SLCO3A1—retina—malignant glioma	0.000763	0.0115	CbGeAlD
Methotrexate—Petechiae—Temozolomide—malignant glioma	0.000746	0.00575	CcSEcCtD
Methotrexate—Speech disorder—Carmustine—malignant glioma	0.000738	0.00569	CcSEcCtD
Methotrexate—Extravasation—Carmustine—malignant glioma	0.000727	0.00561	CcSEcCtD
Methotrexate—MTHFR—telencephalon—malignant glioma	0.000714	0.0107	CbGeAlD
Methotrexate—Speech disorder—Temozolomide—malignant glioma	0.000713	0.0055	CcSEcCtD
Methotrexate—DHFR—retina—malignant glioma	0.000701	0.0105	CbGeAlD
Methotrexate—FPGS—spinal cord—malignant glioma	0.000696	0.0105	CbGeAlD
Methotrexate—ATIC—midbrain—malignant glioma	0.00069	0.0104	CbGeAlD
Methotrexate—Hyperbilirubinaemia—Temozolomide—malignant glioma	0.000675	0.0052	CcSEcCtD
Methotrexate—PGD—retina—malignant glioma	0.000674	0.0101	CbGeAlD
Methotrexate—ATIC—spinal cord—malignant glioma	0.000673	0.0101	CbGeAlD
Methotrexate—SLC19A1—brain—malignant glioma	0.000672	0.0101	CbGeAlD
Methotrexate—Herpes simplex—Temozolomide—malignant glioma	0.000666	0.00513	CcSEcCtD
Methotrexate—SLC46A1—central nervous system—malignant glioma	0.000653	0.00981	CbGeAlD
Methotrexate—TYMS—telencephalon—malignant glioma	0.000651	0.00979	CbGeAlD
Methotrexate—Hepatic enzyme increased—Temozolomide—malignant glioma	0.000648	0.005	CcSEcCtD
Methotrexate—DHFR—telencephalon—malignant glioma	0.000645	0.00969	CbGeAlD
Methotrexate—GGH—central nervous system—malignant glioma	0.000642	0.00965	CbGeAlD
Methotrexate—SLC46A1—cerebellum—malignant glioma	0.000638	0.00959	CbGeAlD
Methotrexate—Pulmonary embolism—Carmustine—malignant glioma	0.000635	0.0049	CcSEcCtD
Methotrexate—SLC16A1—retina—malignant glioma	0.000629	0.00946	CbGeAlD
Methotrexate—GGH—cerebellum—malignant glioma	0.000627	0.00943	CbGeAlD
Methotrexate—Respiratory failure—Temozolomide—malignant glioma	0.000625	0.00482	CcSEcCtD
Methotrexate—PGD—telencephalon—malignant glioma	0.00062	0.00932	CbGeAlD
Methotrexate—Vaginal inflammation—Temozolomide—malignant glioma	0.000613	0.00473	CcSEcCtD
Methotrexate—Pulmonary embolism—Temozolomide—malignant glioma	0.000613	0.00473	CcSEcCtD
Methotrexate—Depressed level of consciousness—Carmustine—malignant glioma	0.000613	0.00473	CcSEcCtD
Methotrexate—Skin exfoliation—Carmustine—malignant glioma	0.000606	0.00467	CcSEcCtD
Methotrexate—Depressed level of consciousness—Temozolomide—malignant glioma	0.000592	0.00457	CcSEcCtD
Methotrexate—Skin exfoliation—Temozolomide—malignant glioma	0.000586	0.00452	CcSEcCtD
Methotrexate—Coma—Carmustine—malignant glioma	0.00058	0.00447	CcSEcCtD
Methotrexate—Vaginal infection—Temozolomide—malignant glioma	0.000579	0.00447	CcSEcCtD
Methotrexate—SLC16A1—telencephalon—malignant glioma	0.000579	0.0087	CbGeAlD
Methotrexate—Aplastic anaemia—Temozolomide—malignant glioma	0.000576	0.00444	CcSEcCtD
Methotrexate—Neoplasm—Carmustine—malignant glioma	0.000574	0.00443	CcSEcCtD
Methotrexate—SLCO1C1—midbrain—malignant glioma	0.000573	0.00862	CbGeAlD
Methotrexate—Gynaecomastia—Carmustine—malignant glioma	0.000568	0.00438	CcSEcCtD
Methotrexate—FPGS—central nervous system—malignant glioma	0.000564	0.00848	CbGeAlD
Methotrexate—SLCO1C1—spinal cord—malignant glioma	0.000559	0.00841	CbGeAlD
Methotrexate—Neoplasm—Temozolomide—malignant glioma	0.000555	0.00428	CcSEcCtD
Methotrexate—SLCO3A1—medulla oblongata—malignant glioma	0.000552	0.0083	CbGeAlD
Methotrexate—FPGS—cerebellum—malignant glioma	0.000552	0.00829	CbGeAlD
Methotrexate—Sepsis—Carmustine—malignant glioma	0.000551	0.00425	CcSEcCtD
Methotrexate—ATIC—central nervous system—malignant glioma	0.000546	0.00821	CbGeAlD
Methotrexate—ATIC—cerebellum—malignant glioma	0.000534	0.00802	CbGeAlD
Methotrexate—Thrombophlebitis—Carmustine—malignant glioma	0.000532	0.00411	CcSEcCtD
Methotrexate—ABCC10—telencephalon—malignant glioma	0.000532	0.00799	CbGeAlD
Methotrexate—Diabetes mellitus—Carmustine—malignant glioma	0.00053	0.00409	CcSEcCtD
Methotrexate—SLC46A1—brain—malignant glioma	0.000518	0.00779	CbGeAlD
Methotrexate—Thrombophlebitis—Temozolomide—malignant glioma	0.000514	0.00397	CcSEcCtD
Methotrexate—GGH—brain—malignant glioma	0.00051	0.00766	CbGeAlD
Methotrexate—DHFR—medulla oblongata—malignant glioma	0.000507	0.00762	CbGeAlD
Methotrexate—SLCO3A1—midbrain—malignant glioma	0.000504	0.00758	CbGeAlD
Methotrexate—Hepatic failure—Temozolomide—malignant glioma	0.000495	0.00382	CcSEcCtD
Methotrexate—SLCO3A1—spinal cord—malignant glioma	0.000492	0.0074	CbGeAlD
Methotrexate—PGD—medulla oblongata—malignant glioma	0.000487	0.00732	CbGeAlD
Methotrexate—Dermatitis exfoliative—Temozolomide—malignant glioma	0.000472	0.00364	CcSEcCtD
Methotrexate—TYMS—midbrain—malignant glioma	0.000468	0.00703	CbGeAlD
Methotrexate—DHFR—midbrain—malignant glioma	0.000463	0.00696	CbGeAlD
Methotrexate—SLCO1A2—telencephalon—malignant glioma	0.000458	0.00689	CbGeAlD
Methotrexate—SLC16A1—medulla oblongata—malignant glioma	0.000455	0.00684	CbGeAlD
Methotrexate—SLCO1C1—central nervous system—malignant glioma	0.000454	0.00682	CbGeAlD
Methotrexate—DHFR—spinal cord—malignant glioma	0.000452	0.00679	CbGeAlD
Methotrexate—FPGS—brain—malignant glioma	0.000448	0.00674	CbGeAlD
Methotrexate—PGD—midbrain—malignant glioma	0.000445	0.00669	CbGeAlD
Methotrexate—PGD—spinal cord—malignant glioma	0.000434	0.00653	CbGeAlD
Methotrexate—ATIC—brain—malignant glioma	0.000433	0.00652	CbGeAlD
Methotrexate—Ataxia—Carmustine—malignant glioma	0.000433	0.00334	CcSEcCtD
Methotrexate—Liver function test abnormal—Carmustine—malignant glioma	0.000425	0.00328	CcSEcCtD
Methotrexate—Mood swings—Temozolomide—malignant glioma	0.000422	0.00325	CcSEcCtD
Methotrexate—Ataxia—Temozolomide—malignant glioma	0.000419	0.00323	CcSEcCtD
Methotrexate—ABCC10—medulla oblongata—malignant glioma	0.000418	0.00628	CbGeAlD
Methotrexate—SLC16A1—midbrain—malignant glioma	0.000416	0.00625	CbGeAlD
Methotrexate—MTHFR—central nervous system—malignant glioma	0.000406	0.0061	CbGeAlD
Methotrexate—SLC16A1—spinal cord—malignant glioma	0.000406	0.0061	CbGeAlD
Methotrexate—Breast disorder—Temozolomide—malignant glioma	0.000402	0.0031	CcSEcCtD
Methotrexate—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.000401	0.00309	CcSEcCtD
Methotrexate—SLCO3A1—central nervous system—malignant glioma	0.000399	0.006	CbGeAlD
Methotrexate—MTHFR—cerebellum—malignant glioma	0.000397	0.00596	CbGeAlD
Methotrexate—SLCO3A1—cerebellum—malignant glioma	0.00039	0.00587	CbGeAlD
Methotrexate—ABCC10—midbrain—malignant glioma	0.000382	0.00574	CbGeAlD
Methotrexate—Pancytopenia—Carmustine—malignant glioma	0.000378	0.00292	CcSEcCtD
Methotrexate—ABCC1—telencephalon—malignant glioma	0.000376	0.00565	CbGeAlD
Methotrexate—ABCC10—spinal cord—malignant glioma	0.000372	0.0056	CbGeAlD
Methotrexate—Neutropenia—Carmustine—malignant glioma	0.000372	0.00287	CcSEcCtD
Methotrexate—TYMS—central nervous system—malignant glioma	0.00037	0.00557	CbGeAlD
Methotrexate—DHFR—central nervous system—malignant glioma	0.000367	0.00551	CbGeAlD
Methotrexate—Pancytopenia—Temozolomide—malignant glioma	0.000365	0.00282	CcSEcCtD
Methotrexate—TYMS—cerebellum—malignant glioma	0.000362	0.00544	CbGeAlD
Methotrexate—SLCO1C1—brain—malignant glioma	0.00036	0.00542	CbGeAlD
Methotrexate—SLCO1A2—medulla oblongata—malignant glioma	0.00036	0.00541	CbGeAlD
Methotrexate—Neutropenia—Temozolomide—malignant glioma	0.00036	0.00278	CcSEcCtD
Methotrexate—Dysuria—Temozolomide—malignant glioma	0.00036	0.00278	CcSEcCtD
Methotrexate—DHFR—cerebellum—malignant glioma	0.000358	0.00539	CbGeAlD
Methotrexate—Upper respiratory tract infection—Temozolomide—malignant glioma	0.000358	0.00276	CcSEcCtD
Methotrexate—Pneumonia—Carmustine—malignant glioma	0.000357	0.00275	CcSEcCtD
Methotrexate—Erectile dysfunction—Temozolomide—malignant glioma	0.000354	0.00273	CcSEcCtD
Methotrexate—Depression—Carmustine—malignant glioma	0.000354	0.00273	CcSEcCtD
Methotrexate—PGD—central nervous system—malignant glioma	0.000352	0.0053	CbGeAlD
Methotrexate—Photosensitivity reaction—Temozolomide—malignant glioma	0.000351	0.00271	CcSEcCtD
Methotrexate—Renal failure—Carmustine—malignant glioma	0.000349	0.00269	CcSEcCtD
Methotrexate—Stomatitis—Carmustine—malignant glioma	0.000346	0.00267	CcSEcCtD
Methotrexate—Pneumonia—Temozolomide—malignant glioma	0.000345	0.00266	CcSEcCtD
Methotrexate—PGD—cerebellum—malignant glioma	0.000344	0.00518	CbGeAlD
Methotrexate—Infestation—Temozolomide—malignant glioma	0.000343	0.00265	CcSEcCtD
Methotrexate—Infestation NOS—Temozolomide—malignant glioma	0.000343	0.00265	CcSEcCtD
Methotrexate—Depression—Temozolomide—malignant glioma	0.000342	0.00264	CcSEcCtD
Methotrexate—SLC22A7—brain—malignant glioma	0.000342	0.00513	CbGeAlD
Methotrexate—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.00034	0.00262	CcSEcCtD
Methotrexate—Stomatitis—Temozolomide—malignant glioma	0.000334	0.00258	CcSEcCtD
Methotrexate—SLC22A6—brain—malignant glioma	0.00033	0.00496	CbGeAlD
Methotrexate—SLCO1A2—midbrain—malignant glioma	0.000329	0.00495	CbGeAlD
Methotrexate—SLC16A1—central nervous system—malignant glioma	0.000329	0.00495	CbGeAlD
Methotrexate—Hepatobiliary disease—Temozolomide—malignant glioma	0.000325	0.0025	CcSEcCtD
Methotrexate—MTHFR—brain—malignant glioma	0.000322	0.00484	CbGeAlD
Methotrexate—SLC16A1—cerebellum—malignant glioma	0.000322	0.00483	CbGeAlD
Methotrexate—SLCO1A2—spinal cord—malignant glioma	0.000321	0.00483	CbGeAlD
Methotrexate—Haemoglobin—Carmustine—malignant glioma	0.00032	0.00247	CcSEcCtD
Methotrexate—Haemorrhage—Carmustine—malignant glioma	0.000319	0.00246	CcSEcCtD
Methotrexate—SLCO3A1—brain—malignant glioma	0.000317	0.00476	CbGeAlD
Methotrexate—ABCB1—blood vessel—malignant glioma	0.000316	0.00476	CbGeAlD
Methotrexate—ABCG2—telencephalon—malignant glioma	0.000311	0.00468	CbGeAlD
Methotrexate—Haemoglobin—Temozolomide—malignant glioma	0.00031	0.00239	CcSEcCtD
Methotrexate—Haemorrhage—Temozolomide—malignant glioma	0.000308	0.00238	CcSEcCtD
Methotrexate—Hepatitis—Temozolomide—malignant glioma	0.000308	0.00238	CcSEcCtD
Methotrexate—Visual impairment—Carmustine—malignant glioma	0.000307	0.00237	CcSEcCtD
Methotrexate—Pharyngitis—Temozolomide—malignant glioma	0.000306	0.00236	CcSEcCtD
Methotrexate—Urinary tract disorder—Temozolomide—malignant glioma	0.000304	0.00235	CcSEcCtD
Methotrexate—ABCC3—central nervous system—malignant glioma	0.000304	0.00456	CbGeAlD
Methotrexate—AOX1—cerebellum—malignant glioma	0.000303	0.00456	CbGeAlD
Methotrexate—Urethral disorder—Temozolomide—malignant glioma	0.000302	0.00233	CcSEcCtD
Methotrexate—Eye disorder—Carmustine—malignant glioma	0.000298	0.0023	CcSEcCtD
Methotrexate—Visual impairment—Temozolomide—malignant glioma	0.000297	0.00229	CcSEcCtD
Methotrexate—ABCC10—cerebellum—malignant glioma	0.000295	0.00444	CbGeAlD
Methotrexate—TYMS—brain—malignant glioma	0.000294	0.00442	CbGeAlD
Methotrexate—Erythema multiforme—Temozolomide—malignant glioma	0.000291	0.00225	CcSEcCtD
Methotrexate—DHFR—brain—malignant glioma	0.000291	0.00437	CbGeAlD
Methotrexate—Eye disorder—Temozolomide—malignant glioma	0.000288	0.00222	CcSEcCtD
Methotrexate—Tinnitus—Temozolomide—malignant glioma	0.000287	0.00222	CcSEcCtD
Methotrexate—Cardiac disorder—Temozolomide—malignant glioma	0.000286	0.00221	CcSEcCtD
Methotrexate—Alopecia—Carmustine—malignant glioma	0.000282	0.00217	CcSEcCtD
Methotrexate—PGD—brain—malignant glioma	0.00028	0.00421	CbGeAlD
Methotrexate—Angiopathy—Temozolomide—malignant glioma	0.000279	0.00216	CcSEcCtD
Methotrexate—Mental disorder—Carmustine—malignant glioma	0.000279	0.00215	CcSEcCtD
Methotrexate—Immune system disorder—Temozolomide—malignant glioma	0.000278	0.00215	CcSEcCtD
Methotrexate—Mediastinal disorder—Temozolomide—malignant glioma	0.000278	0.00214	CcSEcCtD
Methotrexate—Malnutrition—Carmustine—malignant glioma	0.000277	0.00214	CcSEcCtD
Methotrexate—Erythema—Carmustine—malignant glioma	0.000277	0.00214	CcSEcCtD
Methotrexate—Chills—Temozolomide—malignant glioma	0.000276	0.00213	CcSEcCtD
Methotrexate—Alopecia—Temozolomide—malignant glioma	0.000272	0.0021	CcSEcCtD
Methotrexate—Mental disorder—Temozolomide—malignant glioma	0.00027	0.00208	CcSEcCtD
Methotrexate—Back pain—Carmustine—malignant glioma	0.000268	0.00207	CcSEcCtD
Methotrexate—Malnutrition—Temozolomide—malignant glioma	0.000268	0.00207	CcSEcCtD
Methotrexate—Erythema—Temozolomide—malignant glioma	0.000268	0.00207	CcSEcCtD
Methotrexate—Dysgeusia—Temozolomide—malignant glioma	0.000263	0.00203	CcSEcCtD
Methotrexate—Vision blurred—Carmustine—malignant glioma	0.000261	0.00202	CcSEcCtD
Methotrexate—SLC16A1—brain—malignant glioma	0.000261	0.00393	CbGeAlD
Methotrexate—SLCO1A2—central nervous system—malignant glioma	0.00026	0.00392	CbGeAlD
Methotrexate—Back pain—Temozolomide—malignant glioma	0.000259	0.002	CcSEcCtD
Methotrexate—Anaemia—Carmustine—malignant glioma	0.000256	0.00198	CcSEcCtD
Methotrexate—SLCO1A2—cerebellum—malignant glioma	0.000255	0.00383	CbGeAlD
Methotrexate—Vision blurred—Temozolomide—malignant glioma	0.000253	0.00195	CcSEcCtD
Methotrexate—ABCC4—central nervous system—malignant glioma	0.000251	0.00377	CbGeAlD
Methotrexate—Ill-defined disorder—Temozolomide—malignant glioma	0.000249	0.00192	CcSEcCtD
Methotrexate—SLC22A8—central nervous system—malignant glioma	0.000249	0.00374	CbGeAlD
Methotrexate—Leukopenia—Carmustine—malignant glioma	0.000248	0.00192	CcSEcCtD
Methotrexate—Anaemia—Temozolomide—malignant glioma	0.000248	0.00191	CcSEcCtD
Methotrexate—AOX1—brain—malignant glioma	0.000246	0.00371	CbGeAlD
Methotrexate—ABCG2—medulla oblongata—malignant glioma	0.000245	0.00368	CbGeAlD
Methotrexate—Malaise—Temozolomide—malignant glioma	0.000242	0.00187	CcSEcCtD
Methotrexate—ABCC3—brain—malignant glioma	0.000241	0.00362	CbGeAlD
Methotrexate—Vertigo—Temozolomide—malignant glioma	0.000241	0.00186	CcSEcCtD
Methotrexate—Convulsion—Carmustine—malignant glioma	0.00024	0.00185	CcSEcCtD
Methotrexate—Leukopenia—Temozolomide—malignant glioma	0.00024	0.00185	CcSEcCtD
Methotrexate—ABCC10—brain—malignant glioma	0.00024	0.00361	CbGeAlD
Methotrexate—Myalgia—Carmustine—malignant glioma	0.000236	0.00182	CcSEcCtD
Methotrexate—Chest pain—Carmustine—malignant glioma	0.000236	0.00182	CcSEcCtD
Methotrexate—Cough—Temozolomide—malignant glioma	0.000234	0.00181	CcSEcCtD
Methotrexate—Convulsion—Temozolomide—malignant glioma	0.000232	0.00179	CcSEcCtD
Methotrexate—Confusional state—Carmustine—malignant glioma	0.000228	0.00176	CcSEcCtD
Methotrexate—Myalgia—Temozolomide—malignant glioma	0.000228	0.00176	CcSEcCtD
Methotrexate—Arthralgia—Temozolomide—malignant glioma	0.000228	0.00176	CcSEcCtD
Methotrexate—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000227	0.00175	CcSEcCtD
Methotrexate—Discomfort—Temozolomide—malignant glioma	0.000226	0.00174	CcSEcCtD
Methotrexate—Infection—Carmustine—malignant glioma	0.000225	0.00174	CcSEcCtD
Methotrexate—ABCG2—midbrain—malignant glioma	0.000224	0.00336	CbGeAlD
Methotrexate—Thrombocytopenia—Carmustine—malignant glioma	0.000222	0.00171	CcSEcCtD
Methotrexate—Confusional state—Temozolomide—malignant glioma	0.000221	0.0017	CcSEcCtD
Methotrexate—Anaphylactic shock—Temozolomide—malignant glioma	0.000219	0.00169	CcSEcCtD
Methotrexate—ABCG2—spinal cord—malignant glioma	0.000218	0.00328	CbGeAlD
Methotrexate—Infection—Temozolomide—malignant glioma	0.000217	0.00168	CcSEcCtD
Methotrexate—Anorexia—Carmustine—malignant glioma	0.000216	0.00167	CcSEcCtD
Methotrexate—Nervous system disorder—Temozolomide—malignant glioma	0.000215	0.00166	CcSEcCtD
Methotrexate—Thrombocytopenia—Temozolomide—malignant glioma	0.000214	0.00165	CcSEcCtD
Methotrexate—Skin disorder—Temozolomide—malignant glioma	0.000213	0.00164	CcSEcCtD
Methotrexate—Hypotension—Carmustine—malignant glioma	0.000212	0.00163	CcSEcCtD
Methotrexate—Hyperhidrosis—Temozolomide—malignant glioma	0.000212	0.00163	CcSEcCtD
Methotrexate—ABCC1—cerebellum—malignant glioma	0.000209	0.00314	CbGeAlD
Methotrexate—Anorexia—Temozolomide—malignant glioma	0.000209	0.00161	CcSEcCtD
Methotrexate—SLCO1A2—brain—malignant glioma	0.000207	0.00311	CbGeAlD
Methotrexate—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000206	0.00159	CcSEcCtD
Methotrexate—ALB—brain—malignant glioma	0.000206	0.00309	CbGeAlD
Methotrexate—Insomnia—Carmustine—malignant glioma	0.000205	0.00158	CcSEcCtD
Methotrexate—Paraesthesia—Carmustine—malignant glioma	0.000203	0.00157	CcSEcCtD
Methotrexate—Dyspnoea—Carmustine—malignant glioma	0.000202	0.00156	CcSEcCtD
Methotrexate—Somnolence—Carmustine—malignant glioma	0.000201	0.00155	CcSEcCtD
Methotrexate—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000199	0.00154	CcSEcCtD
Methotrexate—ABCC4—brain—malignant glioma	0.000199	0.00299	CbGeAlD
Methotrexate—Insomnia—Temozolomide—malignant glioma	0.000198	0.00153	CcSEcCtD
Methotrexate—SLC22A8—brain—malignant glioma	0.000197	0.00297	CbGeAlD
Methotrexate—Decreased appetite—Carmustine—malignant glioma	0.000197	0.00152	CcSEcCtD
Methotrexate—Paraesthesia—Temozolomide—malignant glioma	0.000197	0.00152	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Carmustine—malignant glioma	0.000196	0.00151	CcSEcCtD
Methotrexate—Dyspnoea—Temozolomide—malignant glioma	0.000195	0.00151	CcSEcCtD
Methotrexate—Somnolence—Temozolomide—malignant glioma	0.000195	0.0015	CcSEcCtD
Methotrexate—Pain—Carmustine—malignant glioma	0.000194	0.00149	CcSEcCtD
Methotrexate—Dyspepsia—Temozolomide—malignant glioma	0.000193	0.00149	CcSEcCtD
Methotrexate—Decreased appetite—Temozolomide—malignant glioma	0.00019	0.00147	CcSEcCtD
Methotrexate—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000189	0.00146	CcSEcCtD
Methotrexate—ABCB1—embryo—malignant glioma	0.000189	0.00284	CbGeAlD
Methotrexate—Fatigue—Temozolomide—malignant glioma	0.000189	0.00146	CcSEcCtD
Methotrexate—Pain—Temozolomide—malignant glioma	0.000187	0.00144	CcSEcCtD
Methotrexate—Feeling abnormal—Carmustine—malignant glioma	0.000187	0.00144	CcSEcCtD
Methotrexate—Gastrointestinal pain—Carmustine—malignant glioma	0.000185	0.00143	CcSEcCtD
Methotrexate—Feeling abnormal—Temozolomide—malignant glioma	0.00018	0.00139	CcSEcCtD
Methotrexate—Body temperature increased—Carmustine—malignant glioma	0.000179	0.00138	CcSEcCtD
Methotrexate—Abdominal pain—Carmustine—malignant glioma	0.000179	0.00138	CcSEcCtD
Methotrexate—Gastrointestinal pain—Temozolomide—malignant glioma	0.000179	0.00138	CcSEcCtD
Methotrexate—Urticaria—Temozolomide—malignant glioma	0.000174	0.00134	CcSEcCtD
Methotrexate—Body temperature increased—Temozolomide—malignant glioma	0.000173	0.00133	CcSEcCtD
Methotrexate—Abdominal pain—Temozolomide—malignant glioma	0.000173	0.00133	CcSEcCtD
Methotrexate—ABCG2—cerebellum—malignant glioma	0.000173	0.0026	CbGeAlD
Methotrexate—ABCC1—brain—malignant glioma	0.00017	0.00255	CbGeAlD
Methotrexate—ABCB1—retina—malignant glioma	0.000167	0.00251	CbGeAlD
Methotrexate—Hypersensitivity—Carmustine—malignant glioma	0.000167	0.00129	CcSEcCtD
Methotrexate—Asthenia—Carmustine—malignant glioma	0.000162	0.00125	CcSEcCtD
Methotrexate—Hypersensitivity—Temozolomide—malignant glioma	0.000161	0.00124	CcSEcCtD
Methotrexate—Asthenia—Temozolomide—malignant glioma	0.000157	0.00121	CcSEcCtD
Methotrexate—Diarrhoea—Carmustine—malignant glioma	0.000155	0.0012	CcSEcCtD
Methotrexate—Pruritus—Temozolomide—malignant glioma	0.000155	0.00119	CcSEcCtD
Methotrexate—ABCB1—telencephalon—malignant glioma	0.000153	0.00231	CbGeAlD
Methotrexate—Dizziness—Carmustine—malignant glioma	0.00015	0.00116	CcSEcCtD
Methotrexate—Diarrhoea—Temozolomide—malignant glioma	0.00015	0.00116	CcSEcCtD
Methotrexate—Dizziness—Temozolomide—malignant glioma	0.000145	0.00112	CcSEcCtD
Methotrexate—Vomiting—Carmustine—malignant glioma	0.000144	0.00111	CcSEcCtD
Methotrexate—Rash—Carmustine—malignant glioma	0.000143	0.0011	CcSEcCtD
Methotrexate—Dermatitis—Carmustine—malignant glioma	0.000143	0.0011	CcSEcCtD
Methotrexate—Headache—Carmustine—malignant glioma	0.000142	0.00109	CcSEcCtD
Methotrexate—ABCG2—brain—malignant glioma	0.00014	0.00211	CbGeAlD
Methotrexate—Vomiting—Temozolomide—malignant glioma	0.000139	0.00107	CcSEcCtD
Methotrexate—Rash—Temozolomide—malignant glioma	0.000138	0.00106	CcSEcCtD
Methotrexate—Dermatitis—Temozolomide—malignant glioma	0.000138	0.00106	CcSEcCtD
Methotrexate—Headache—Temozolomide—malignant glioma	0.000137	0.00106	CcSEcCtD
Methotrexate—Nausea—Carmustine—malignant glioma	0.000135	0.00104	CcSEcCtD
Methotrexate—Nausea—Temozolomide—malignant glioma	0.00013	0.001	CcSEcCtD
Methotrexate—ABCB1—medulla oblongata—malignant glioma	0.000121	0.00181	CbGeAlD
Methotrexate—ABCB1—midbrain—malignant glioma	0.00011	0.00166	CbGeAlD
Methotrexate—ABCB1—spinal cord—malignant glioma	0.000108	0.00162	CbGeAlD
Methotrexate—ABCB1—central nervous system—malignant glioma	8.72e-05	0.00131	CbGeAlD
Methotrexate—ABCB1—cerebellum—malignant glioma	8.53e-05	0.00128	CbGeAlD
Methotrexate—ABCB1—brain—malignant glioma	6.93e-05	0.00104	CbGeAlD
Methotrexate—FPGS—Metabolism—AKT1—malignant glioma	8.13e-06	8.59e-05	CbGpPWpGaD
Methotrexate—ATIC—Metabolism—AKT1—malignant glioma	8.13e-06	8.59e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CG—malignant glioma	8.1e-06	8.56e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NCOR1—malignant glioma	8.1e-06	8.56e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—PTGS2—malignant glioma	8.07e-06	8.52e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—SLC5A5—malignant glioma	8.06e-06	8.52e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Transmembrane transport of small molecules—RAF1—malignant glioma	8.02e-06	8.47e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CAT—malignant glioma	7.98e-06	8.43e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PTEN—malignant glioma	7.92e-06	8.36e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—VEGFA—malignant glioma	7.82e-06	8.27e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PIK3CD—malignant glioma	7.82e-06	8.26e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PPARG—malignant glioma	7.82e-06	8.26e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—CAV1—malignant glioma	7.82e-06	8.26e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PDGFB—malignant glioma	7.81e-06	8.25e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CG—malignant glioma	7.76e-06	8.2e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PDGFRA—malignant glioma	7.75e-06	8.19e-05	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—PIK3CA—malignant glioma	7.75e-06	8.19e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—PTEN—malignant glioma	7.73e-06	8.17e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—malignant glioma	7.7e-06	8.14e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—IDH2—malignant glioma	7.68e-06	8.12e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PIK3CB—malignant glioma	7.67e-06	8.11e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Hemostasis—AKT1—malignant glioma	7.63e-06	8.06e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PTGS2—malignant glioma	7.6e-06	8.03e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—KRAS—malignant glioma	7.58e-06	8.01e-05	CbGpPWpGaD
Methotrexate—SLC46A1—Disease—AKT1—malignant glioma	7.56e-06	7.99e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—IDH1—malignant glioma	7.54e-06	7.97e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—NCOR1—malignant glioma	7.54e-06	7.96e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PIK3CB—malignant glioma	7.49e-06	7.92e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PPARG—malignant glioma	7.49e-06	7.92e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	7.49e-06	7.91e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	7.47e-06	7.89e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PTGS2—malignant glioma	7.42e-06	7.85e-05	CbGpPWpGaD
Methotrexate—ABCG2—Transmembrane transport of small molecules—RAF1—malignant glioma	7.42e-06	7.85e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—CAV1—malignant glioma	7.4e-06	7.82e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—GSTP1—malignant glioma	7.38e-06	7.8e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SPHK1—malignant glioma	7.29e-06	7.71e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP2B6—malignant glioma	7.22e-06	7.63e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CAT—malignant glioma	7.18e-06	7.59e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CYP2C18—malignant glioma	7.15e-06	7.55e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HLA-A—malignant glioma	7.14e-06	7.54e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—TERT—malignant glioma	7.14e-06	7.54e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CD—malignant glioma	7.12e-06	7.53e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CG—malignant glioma	7.12e-06	7.53e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	7.11e-06	7.52e-05	CbGpPWpGaD
Methotrexate—PGD—Metabolism—PIK3CA—malignant glioma	7.09e-06	7.49e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—malignant glioma	7.09e-06	7.49e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—STAT3—malignant glioma	7.08e-06	7.48e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—CAV1—malignant glioma	7.05e-06	7.45e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—FN1—malignant glioma	7.05e-06	7.45e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—F2—malignant glioma	7.05e-06	7.45e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—PTEN—malignant glioma	7.03e-06	7.43e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—GSTP1—malignant glioma	7.01e-06	7.41e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PDGFB—malignant glioma	6.96e-06	7.36e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—PIK3CA—malignant glioma	6.96e-06	7.36e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—malignant glioma	6.93e-06	7.33e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—FGFR1—malignant glioma	6.93e-06	7.32e-05	CbGpPWpGaD
Methotrexate—PGD—Disease—AKT1—malignant glioma	6.91e-06	7.31e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—STAT3—malignant glioma	6.91e-06	7.31e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PPARG—malignant glioma	6.87e-06	7.26e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CD—malignant glioma	6.82e-06	7.21e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—HIF1A—malignant glioma	6.82e-06	7.21e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CAT—malignant glioma	6.82e-06	7.21e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PIK3CB—malignant glioma	6.82e-06	7.2e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—NCOR1—malignant glioma	6.78e-06	7.17e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTGS2—malignant glioma	6.75e-06	7.14e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CG—malignant glioma	6.74e-06	7.13e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	6.74e-06	7.12e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	6.74e-06	7.12e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—TP53—malignant glioma	6.73e-06	7.12e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—EGF—malignant glioma	6.66e-06	7.04e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PTEN—malignant glioma	6.63e-06	7.01e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PTPN11—malignant glioma	6.62e-06	7e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—IDH1—malignant glioma	6.61e-06	6.98e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—malignant glioma	6.6e-06	6.98e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CAV1—malignant glioma	6.6e-06	6.97e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—MYC—malignant glioma	6.58e-06	6.95e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—malignant glioma	6.55e-06	6.92e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—GSTP1—malignant glioma	6.49e-06	6.86e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PTEN—malignant glioma	6.47e-06	6.84e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—NCOR1—malignant glioma	6.44e-06	6.81e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—EGFR—malignant glioma	6.43e-06	6.8e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CG—malignant glioma	6.43e-06	6.79e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—MYC—malignant glioma	6.42e-06	6.79e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SPHK1—malignant glioma	6.39e-06	6.75e-05	CbGpPWpGaD
Methotrexate—SLC46A1—Metabolism—AKT1—malignant glioma	6.33e-06	6.69e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CAT—malignant glioma	6.32e-06	6.68e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—STAT3—malignant glioma	6.29e-06	6.65e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—EGFR—malignant glioma	6.28e-06	6.64e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CYP2C18—malignant glioma	6.26e-06	6.62e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CD—malignant glioma	6.26e-06	6.62e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CB—malignant glioma	6.21e-06	6.56e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—BAD—malignant glioma	6.21e-06	6.56e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PPARG—malignant glioma	6.2e-06	6.55e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—AKT2—malignant glioma	6.17e-06	6.52e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTGS2—malignant glioma	6.15e-06	6.5e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—NOTCH1—malignant glioma	6.15e-06	6.5e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—CAV1—malignant glioma	6.14e-06	6.49e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	6.14e-06	6.49e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—PIK3CA—malignant glioma	6.11e-06	6.46e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—KRAS—malignant glioma	6.08e-06	6.42e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—CD80—malignant glioma	6.02e-06	6.36e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—malignant glioma	6.02e-06	6.36e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—APC—malignant glioma	6.01e-06	6.35e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—NCOR1—malignant glioma	5.97e-06	6.31e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CB—malignant glioma	5.95e-06	6.29e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EGF—malignant glioma	5.94e-06	6.28e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—KRAS—malignant glioma	5.94e-06	6.27e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CD—malignant glioma	5.93e-06	6.26e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	5.92e-06	6.26e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTPN11—malignant glioma	5.91e-06	6.24e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTGS2—malignant glioma	5.89e-06	6.23e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PTEN—malignant glioma	5.89e-06	6.23e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	5.87e-06	6.2e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—MYC—malignant glioma	5.85e-06	6.18e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—malignant glioma	5.82e-06	6.15e-05	CbGpPWpGaD
Methotrexate—PGD—Metabolism—AKT1—malignant glioma	5.79e-06	6.12e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTT1—malignant glioma	5.78e-06	6.11e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—EGFR—malignant glioma	5.72e-06	6.04e-05	CbGpPWpGaD
Methotrexate—ABCC4—Hemostasis—AKT1—malignant glioma	5.69e-06	6.01e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—BRAF—malignant glioma	5.65e-06	5.97e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CD—malignant glioma	5.65e-06	5.97e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CG—malignant glioma	5.6e-06	5.91e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—PIK3CA—malignant glioma	5.58e-06	5.9e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—CAV1—malignant glioma	5.53e-06	5.84e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—AKT2—malignant glioma	5.5e-06	5.81e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CB—malignant glioma	5.46e-06	5.77e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—PIK3CA—malignant glioma	5.45e-06	5.76e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTGS1—malignant glioma	5.42e-06	5.72e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTGS2—malignant glioma	5.41e-06	5.71e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—KRAS—malignant glioma	5.4e-06	5.71e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PPARG—malignant glioma	5.4e-06	5.71e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	5.4e-06	5.7e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PTEN—malignant glioma	5.37e-06	5.67e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—RAF1—malignant glioma	5.29e-06	5.59e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CD—malignant glioma	5.29e-06	5.59e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	5.28e-06	5.58e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—CAV1—malignant glioma	5.25e-06	5.55e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CB—malignant glioma	5.17e-06	5.46e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PTEN—malignant glioma	5.14e-06	5.43e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTT1—malignant glioma	5.06e-06	5.35e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—FGF2—malignant glioma	5.06e-06	5.35e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—BCHE—malignant glioma	5.04e-06	5.32e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CG—malignant glioma	5.03e-06	5.32e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	5.02e-06	5.3e-05	CbGpPWpGaD
Methotrexate—ALB—Platelet activation, signaling and aggregation—AKT1—malignant glioma	4.99e-06	5.27e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—SLC5A5—malignant glioma	4.97e-06	5.26e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—PIK3CA—malignant glioma	4.96e-06	5.24e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CB—malignant glioma	4.92e-06	5.2e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CD—malignant glioma	4.92e-06	5.2e-05	CbGpPWpGaD
Methotrexate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—malignant glioma	4.91e-06	5.19e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTGS2—malignant glioma	4.88e-06	5.16e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—CAV1—malignant glioma	4.86e-06	5.14e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PPARG—malignant glioma	4.86e-06	5.14e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CG—malignant glioma	4.78e-06	5.06e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTGS1—malignant glioma	4.75e-06	5.01e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—IL2—malignant glioma	4.74e-06	5.01e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MDM2—malignant glioma	4.73e-06	5e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—RAF1—malignant glioma	4.72e-06	4.99e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PTEN—malignant glioma	4.72e-06	4.98e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	4.7e-06	4.97e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—PIK3CA—malignant glioma	4.68e-06	4.94e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—ERBB2—malignant glioma	4.67e-06	4.93e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	4.66e-06	4.93e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PPARG—malignant glioma	4.62e-06	4.88e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CB—malignant glioma	4.61e-06	4.87e-05	CbGpPWpGaD
Methotrexate—ALB—Transmembrane transport of small molecules—RAF1—malignant glioma	4.58e-06	4.84e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—PIK3CA—malignant glioma	4.57e-06	4.83e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTGS2—malignant glioma	4.56e-06	4.82e-05	CbGpPWpGaD
Methotrexate—MTHFR—Disease—AKT1—malignant glioma	4.56e-06	4.82e-05	CbGpPWpGaD
Methotrexate—AOX1—Disease—AKT1—malignant glioma	4.46e-06	4.71e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CG—malignant glioma	4.43e-06	4.68e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CD—malignant glioma	4.43e-06	4.68e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—BCHE—malignant glioma	4.41e-06	4.66e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—SLC5A5—malignant glioma	4.36e-06	4.61e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CB—malignant glioma	4.29e-06	4.53e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PPARG—malignant glioma	4.28e-06	4.52e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PTEN—malignant glioma	4.25e-06	4.5e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTGS2—malignant glioma	4.25e-06	4.49e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CD—malignant glioma	4.21e-06	4.45e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—PIK3CA—malignant glioma	4.16e-06	4.39e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	4.06e-06	4.3e-05	CbGpPWpGaD
Methotrexate—DHFR—Disease—AKT1—malignant glioma	4.05e-06	4.28e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—VEGFA—malignant glioma	4.03e-06	4.26e-05	CbGpPWpGaD
Methotrexate—ABCB1—Transmembrane transport of small molecules—RAF1—malignant glioma	4.01e-06	4.24e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—GSTP1—malignant glioma	4.01e-06	4.23e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PTEN—malignant glioma	3.98e-06	4.21e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CAT—malignant glioma	3.9e-06	4.12e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CD—malignant glioma	3.89e-06	4.12e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CB—malignant glioma	3.86e-06	4.08e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTGS2—malignant glioma	3.82e-06	4.04e-05	CbGpPWpGaD
Methotrexate—MTHFR—Metabolism—AKT1—malignant glioma	3.82e-06	4.04e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—PIK3CA—malignant glioma	3.78e-06	4e-05	CbGpPWpGaD
Methotrexate—AOX1—Metabolism—AKT1—malignant glioma	3.73e-06	3.94e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PTEN—malignant glioma	3.7e-06	3.92e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—NCOR1—malignant glioma	3.68e-06	3.89e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CB—malignant glioma	3.67e-06	3.87e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTGS2—malignant glioma	3.63e-06	3.84e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—PIK3CA—malignant glioma	3.63e-06	3.83e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—STAT3—malignant glioma	3.56e-06	3.76e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—GSTP1—malignant glioma	3.51e-06	3.71e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—KRAS—malignant glioma	3.43e-06	3.62e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CAT—malignant glioma	3.42e-06	3.61e-05	CbGpPWpGaD
Methotrexate—DHFR—Metabolism—AKT1—malignant glioma	3.39e-06	3.59e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CB—malignant glioma	3.39e-06	3.59e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTGS2—malignant glioma	3.36e-06	3.55e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PTEN—malignant glioma	3.33e-06	3.52e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—PIK3CA—malignant glioma	3.33e-06	3.52e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—MYC—malignant glioma	3.31e-06	3.5e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—EGFR—malignant glioma	3.24e-06	3.42e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—NCOR1—malignant glioma	3.23e-06	3.41e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PTEN—malignant glioma	3.17e-06	3.35e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—PIK3CA—malignant glioma	3.15e-06	3.33e-05	CbGpPWpGaD
Methotrexate—SLC16A1—Metabolism—AKT1—malignant glioma	3.09e-06	3.27e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—KRAS—malignant glioma	3.06e-06	3.23e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—TP53—malignant glioma	3.05e-06	3.22e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—PIK3CA—malignant glioma	3e-06	3.17e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—CAV1—malignant glioma	3e-06	3.17e-05	CbGpPWpGaD
Methotrexate—TYMS—Metabolism—AKT1—malignant glioma	2.96e-06	3.13e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PTEN—malignant glioma	2.93e-06	3.1e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	2.87e-06	3.03e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—PIK3CA—malignant glioma	2.81e-06	2.97e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CG—malignant glioma	2.73e-06	2.89e-05	CbGpPWpGaD
Methotrexate—SLCO1B3—Metabolism—AKT1—malignant glioma	2.72e-06	2.87e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PPARG—malignant glioma	2.64e-06	2.79e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—CAV1—malignant glioma	2.63e-06	2.78e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—PIK3CA—malignant glioma	2.61e-06	2.76e-05	CbGpPWpGaD
Methotrexate—ALB—Hemostasis—AKT1—malignant glioma	2.57e-06	2.72e-05	CbGpPWpGaD
Methotrexate—ABCC3—Metabolism—AKT1—malignant glioma	2.45e-06	2.59e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CD—malignant glioma	2.4e-06	2.54e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CG—malignant glioma	2.4e-06	2.53e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—PIK3CA—malignant glioma	2.35e-06	2.49e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PPARG—malignant glioma	2.31e-06	2.44e-05	CbGpPWpGaD
Methotrexate—ABCC1—Disease—AKT1—malignant glioma	2.29e-06	2.42e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—PIK3CA—malignant glioma	2.23e-06	2.36e-05	CbGpPWpGaD
Methotrexate—SLCO1A2—Metabolism—AKT1—malignant glioma	2.14e-06	2.26e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CD—malignant glioma	2.11e-06	2.23e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CB—malignant glioma	2.09e-06	2.21e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTGS2—malignant glioma	2.08e-06	2.19e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—PIK3CA—malignant glioma	2.07e-06	2.19e-05	CbGpPWpGaD
Methotrexate—ABCC1—Metabolism—AKT1—malignant glioma	1.92e-06	2.03e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CB—malignant glioma	1.84e-06	1.94e-05	CbGpPWpGaD
Methotrexate—SLCO1B1—Metabolism—AKT1—malignant glioma	1.83e-06	1.93e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTGS2—malignant glioma	1.82e-06	1.92e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PTEN—malignant glioma	1.81e-06	1.91e-05	CbGpPWpGaD
Methotrexate—ABCG2—Metabolism—AKT1—malignant glioma	1.69e-06	1.79e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PTEN—malignant glioma	1.59e-06	1.68e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—PIK3CA—malignant glioma	1.28e-06	1.35e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—PIK3CA—malignant glioma	1.12e-06	1.18e-05	CbGpPWpGaD
Methotrexate—ALB—Metabolism—AKT1—malignant glioma	1.04e-06	1.1e-05	CbGpPWpGaD
Methotrexate—ABCB1—Metabolism—AKT1—malignant glioma	9.14e-07	9.66e-06	CbGpPWpGaD
